| Year |
Citation |
Score |
| 2021 |
Chetty S, Armstrong T, Sharma Kharkwal S, Drewe WC, De Matteis CI, Evangelopoulos D, Bhakta S, Thomas NR. New InhA Inhibitors Based on Expanded Triclosan and -Triclosan Analogues to Develop a New Treatment for Tuberculosis. Pharmaceuticals (Basel, Switzerland). 14. PMID 33919737 DOI: 10.3390/ph14040361 |
0.316 |
|
| 2020 |
Maitra A, Evangelopoulos D, Chrzastek A, Martin LT, Hanrath A, Chapman E, Hailes HC, Lipman M, McHugh TD, Waddell SJ, Bhakta S. Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. The Journal of Antimicrobial Chemotherapy. PMID 32790867 DOI: 10.1093/Jac/Dkaa307 |
0.315 |
|
| 2017 |
Ryan A, Polycarpou E, Lack NA, Evangelopoulos D, Sieg C, Halman A, Bhakta S, Eleftheriadou O, McHugh TD, Keany S, Lowe ED, Ballet R, Abuhammad A, Jacobs WR, Ciulli A, et al. Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach. British Journal of Pharmacology. PMID 28380256 DOI: 10.1111/Bph.13810 |
0.329 |
|
| 2015 |
Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, Bhakta S. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. 32: 50-5. PMID 25809756 DOI: 10.1016/j.ijid.2014.12.031 |
0.309 |
|
| 2013 |
Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. Bmj Open. 3. PMID 23794563 DOI: 10.1136/Bmjopen-2013-002672 |
0.309 |
|
| 2012 |
Abuhammad A, Fullam E, Lowe ED, Staunton D, Kawamura A, Westwood IM, Bhakta S, Garner AC, Wilson DL, Seden PT, Davies SG, Russell AJ, Garman EF, Sim E. Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: an essential enzyme for mycobacterial survival inside macrophages. Plos One. 7: e52790. PMID 23285185 DOI: 10.1371/Journal.Pone.0052790 |
0.304 |
|
| 2010 |
Westwood IM, Bhakta S, Russell AJ, Fullam E, Anderton MC, Kawamura A, Mulvaney AW, Vickers RJ, Bhowruth V, Besra GS, Lalvani A, Davies SG, Sim E. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein & Cell. 1: 82-95. PMID 21204000 DOI: 10.1007/S13238-010-0006-1 |
0.311 |
|
| 2009 |
Gupta A, Bhakta S, Kundu S, Gupta M, Srivastava BS, Srivastava R. Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening. The Journal of Antimicrobial Chemotherapy. 64: 774-81. PMID 19656786 DOI: 10.1093/jac/dkp279 |
0.344 |
|
| 2003 |
Sim E, Pinter K, Mushtaq A, Upton A, Sandy J, Bhakta S, Noble M. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochemical Society Transactions. 31: 615-9. PMID 12773167 DOI: 10.1042/Bst0310615 |
0.302 |
|
| Show low-probability matches. |